Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

LateralCare, a leader in innovative healthcare technology solutions, is proud to announce the appointment of Niobis Queiro as its new Chief Product Officer. With over three decades of expertise in ...

Dr. Kami Parsa, a distinguished oculoplastic and reconstructive surgeon, has been recognized as the 2025 Top Patient Rated Oculoplastic Surgeon in Beverly Hills by Find Local Doctors. This accolade is ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Physician empathy has long been recommended — but not required — in the doctor-patient relationship.However, for a growing ...

Patients were monitored for disease progression via magnetic resonance imaging or computed tomography scan at screening; baseline; 4, 8, 12, and 24 weeks; and then every 3 months until progression of ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Regeneron stock has trended bearishly since ... The cost for a supply of 7mL for IV infusion is $11,178. While this is a very rough estimate, sales of a single vial of the drug to 10% of the ...